Welcome to our dedicated page for Immunic news (Ticker: IMUX), a resource for investors and traders seeking the latest updates and insights on Immunic stock.
Immunic, Inc. develops novel oral therapies for neurologic diseases, with a lead program, vidofludimus calcium (IMU-838), focused on multiple sclerosis. Company news commonly covers clinical and scientific presentations, patent protection for vidofludimus calcium, pipeline updates, and corporate communications tied to its late-stage development strategy.
Updates also include governance changes, board and executive appointments, Nasdaq listing compliance, capital actions such as its reverse stock split, and investor conference participation. Immunic's pipeline references additional earlier-stage programs, including IMU-856 and IMU-381, tied to neurodegenerative, chronic inflammatory, and autoimmune-related disease areas.
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company, will announce its financial results for Q3 2022 on November 3, 2022, before U.S. market opening. The announcement will include a corporate update, followed by a webcast at 8:00 am ET. Immunic is focused on developing selective oral immunology therapies targeting chronic inflammatory and autoimmune diseases, with key products in its pipeline, including IMU-838 for multiple sclerosis and IMU-935 targeting psoriasis.
Immunic, Inc. (Nasdaq: IMUX) announced the results of an interim analysis from its Phase 1b clinical trial of IMU-935 for moderate-to-severe psoriasis. The analysis revealed that the treatment arms did not significantly outperform a high placebo response at four weeks. While no new safety signals were identified, the unexpected high placebo rates were disappointing and will require further investigation. Despite this, the company remains optimistic about IMU-935's potential and will continue its development, with cash reserves expected to fund operations into Q4 2024.
Immunic, Inc. (Nasdaq: IMUX) announced a $60 million PIPE financing agreement to issue 8,696,552 shares at $4.35 per share and 5,096,552 Pre-Funded Warrants at $4.34 each. The deal, with participation from notable investors, is set to close on October 12, 2022. Proceeds will fund clinical development for leading candidates IMU-838, IMU-935, and IMU-856, enhancing Immunic's pipeline for chronic inflammatory and autoimmune diseases. The company also anticipates initial clinical activity data for IMU-935 in psoriasis later this month.
Immunic, Inc. (Nasdaq: IMUX), a biopharmaceutical company focusing on oral immunology therapies for chronic inflammatory diseases, will participate in several conferences in October 2022. Key events include the 30th UEG Week in Vienna (Oct 8-11), where its clinical team will attend; the International Celiac Disease Symposium in Italy (Oct 19-22), featuring a presentation on IMU-856; and BIO-Europe 2022 in Leipzig (Oct 24-26). Additionally, data from the phase 2 trial of vidofludimus calcium (IMU-838) will be presented at ECTRIMS in Amsterdam (Oct 26-28). More details can be found on their website.
Immunic, Inc. (Nasdaq: IMUX) announced favorable results from its Phase 1 clinical trial of IMU-856, indicating a positive safety, tolerability, and pharmacokinetic profile. The trial included single ascending doses (SAD) and multiple ascending doses (MAD) in healthy subjects, where no maximum tolerated dose was reached, and no serious adverse events occurred. The trial is ongoing with patients suffering from celiac disease. Results showed stable plasma concentrations and support the potential of IMU-856 as a first-in-class oral therapy for celiac disease and other gastrointestinal conditions.
Immunic, Inc. (Nasdaq: IMUX) announced its participation in several investor conferences throughout September 2022. Key events include the Citi's 17th Annual BioPharma Conference on September 7-8 in Boston, where CEO Daniel Vitt and Head of Investor Relations Jessica Breu will attend. The Wells Fargo 2022 Healthcare Conference will feature Dr. Vitt in a fireside chat on September 9 at 9:45 am EDT, with a live broadcast available on the company's website. Additionally, Breu will present at the 2022 Ladenburg Thalmann Healthcare Conference on September 29 at 1:00 pm EDT in New York.
Immunic, Inc. (NASDAQ: IMUX) announced receipt of a Notice of Allowance from the USPTO for its patent application 16/646130, covering the composition-of-matter of IMU-856. This patent is expected to provide protection until at least 2038. The license for IMU-856 was acquired from Daiichi Sankyo in 2020. The drug targets intestinal barrier function, aiming to treat gastrointestinal diseases. A phase 1 clinical trial for IMU-856 in celiac disease has commenced, with safety data expected in Q3 2022. This milestone enhances Immunic's intellectual property portfolio.
Immunic (Nasdaq: IMUX) announced its financial results for Q2 2022 and provided updates on its clinical programs. The company reported a net loss of $21.9 million for the quarter, with cash reserves of $88.1 million expected to sustain operations through Q4 2023. Key upcoming clinical milestones include initial activity results for IMU-935 in psoriasis expected in Q4 2022 and unblinded safety data for IMU-856 anticipated in Q3 2022. Immunic remains optimistic about the potential of vidofludimus calcium in multiple sclerosis despite previous challenges in ulcerative colitis trials.
Immunic, Inc. (Nasdaq: IMUX), a biopharmaceutical company focused on chronic inflammatory and autoimmune diseases, announced CEO Daniel Vitt will speak at the 2022 Wedbush PacGrow Virtual Healthcare Conference on August 9, 2022, at 8:00 am ET. The conference runs from August 9-10. A live webcast will be accessible on the company's website, with an archived replay available for 90 days. Immunic is advancing therapies targeting conditions like multiple sclerosis and psoriasis.
Immunic, Inc. (Nasdaq: IMUX) will announce its financial results for Q2 2022, ending June 30, on August 4, 2022, prior to U.S. market opening. A webcast will follow at 8:00 am ET, with registration available through their website. The company develops selective oral immunology therapies aimed at chronic inflammatory and autoimmune diseases, with products like IMU-838 for multiple sclerosis and IMU-935 for psoriasis and prostate cancer.